UC-961 (Cirmtuzumab) in Relapsed or Refractory Chronic Lymphocytic Leukemia
Status:
Completed
Trial end date:
2018-05-01
Target enrollment:
Participant gender:
Summary
The purpose of the study is to investigate the safety of the investigational agent,
cirmtuzumab. Cirmtuzumab is a monoclonal antibody drug designed to attach to a protein,
called ROR1, on the surface of chronic lymphocytic leukemia (CLL) cells to block cell growth
and survival. ROR1 is rarely expressed on healthy cells so the idea is to preferentially get
rid of the cancer cells. Although there is evidence in laboratory animals that cirmtuzumab
can decrease the number of CLL cells, the investigators do not know if this will work in
humans. This drug will be given to humans for the first time in this study. Therefore, the
goal of this study is to see if cirmtuzumab is safe and tolerated in study participants.